Novo Nordisk Expands API Capacity
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd.
The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.
“This investment in expanding our clinical API capacity in Bagsværd is an important step to ensure the continuous progress of our development pipeline. Increasing our API capacity in R&D will be a key enabler in bringing new innovations to the market, and meet the future demand of our patients”, said Jesper Bøving, senior vice president, chemistry, manufacturing and controls (CMC) development.
On Oct. 14, the company completed its $1.1 billion purchase of Forma Therapeutics, a US clinical-stage biopharma focused on treating patients with rare hematologic diseases and cancers. Forma is now a wholly owned subsidiary of Novo Nordisk.
Author: Elaine Burridge, Freelance Journalist
